David Kirsch
David Guy Kirsch is an American oncologist currently the Barbara Levine University Professor at Duke University[1] and an Elected Fellow of the American Association for the Advancement of Science.[2]
Education
He earned his M.D. and Ph.D at Johns Hopkins University School of Medicine in 2000.[3]
Research
His interests are in studying sarcomagenesis, cancer biology and radiation oncology.[2] His highest cited papers are "Conversion of Bcl-2 to a Bax-like death effector by caspases",[4] at 1332 times, and "Restoration of p53 function leads to tumour regression in vivo",[5] at 1320 times, according to Google Scholar.[6]
Publications
- Yoon, SW, Cramer, CK, Miles, DA, Reinsvold, MH, Joo, KM, Kirsch, DG, and Oldham, M. "A precision 3D conformal treatment technique in rats: Application to whole-brain radiotherapy with hippocampal avoidance." Medical physics 44, no. 11 (November 2017): 6008-6017.
- Dodd, RD, Lee, C-L, Overton, T, Huang, W, Eward, WC, Luo, L, Ma, Y, Ingram, DR, Torres, KE, Cardona, DM, Lazar, AJ, and Kirsch, DG. "NF1+/- Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response." Cancer research 77, no. 16 (August 2017): 4486-4497.
- Huang, J, Chen, M, Whitley, MJ, Kuo, H-C, Xu, ES, Walens, A, Mowery, YM, Van Mater, D, Eward, WC, Cardona, DM, Luo, L, Ma, Y, Lopez, OM, Nelson, CE, Robinson-Hamm, JN, Reddy, A, Dave, SS, Gersbach, CA, Dodd, RD, and Kirsch, DG. "Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma." Nature communications 8 (July 10, 2017): 15999-.
- Castle, KD, Chen, M, Wisdom, AJ, and Kirsch, DG. "Genetically engineered mouse models for studying radiation biology." Translational Cancer Research 6, no. S5 (July 2017): S900-S913.
- McConnell, AM, Yao, C, Yeckes, AR, Wang, Y, Selvaggio, AS, Tang, J, Kirsch, DG, and Stripp, BR. "p53 Regulates Progenitor Cell Quiescence and Differentiation in the Airway." Cell reports 17, no. 9 (November 2016): 2173-2182.
gollark: It's actually ported from someone's Haskell implementation but several times faster, so you could just have NFTized output from that anyway.
gollark: I'm sure people will definitely use my fractal art program, random esolangs, deliberately inefficient matrix multiplier program, slow full text search thing, and length terminated strings for evil.
gollark: Perhaps if I had something actually useful (and userfacing) I'd not do that, but meh.
gollark: My projects are all under MIT because I want people to be able to use and adapt them easily.
gollark: Since if you care about obeying copyright law, and are using it for anything other than personal projects you're not likely to share, you can't safely use it or you might randomly be denied access (again, if this is actually enforceable).
References
- "Kirsch Lab". duke.edu. Retrieved December 20, 2017.
- "Three Faculty Elected Fellows AAAS". duke.edu. November 21, 2017. Retrieved December 20, 2017.
- "David Kirsch". duke.edu. Retrieved December 20, 2017.
- Emily H-Y Cheng, David G Kirsch, Rollie J Clem, Rajani Ravi, Michael B Kastan, Atul Bedi, Kazuyoshi Ueno, J Marie Hardwick. Conversion of Bcl-2 to a Bax-like death effector by caspases. 278:5345. Science. 1997
- Andrea Ventura, David G Kirsch, Margaret E McLaughlin, David A Tuveson, Jan Grimm, Laura Lintault, Jamie Newman, Elizabeth E Reczek, Ralph Weissleder, Tyler Jacks. Restoration of p53 function leads to tumour regression in vivo. 445:7128. 661-665. Nature. 2007
- "David Kirsch". Retrieved December 20, 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.